Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$2.92
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.69 - $5.17
Previous CloseN/A
Volume165.25K
Average Volume (3M)3.51M
Market Cap
$407.99M
Enterprise Value$154.35
Total Cash (Recent Filing)$235.67M
Total Debt (Recent Filing)$58.45M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 12, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume3,448,827
30 Day Avg. Volume3,508,928
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.33Price Target Upside253.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$22.84M
Bulls Say, Bears Say
Bulls Say
Strategic Roche CollaborationThe Roche collaboration provides external validation, development resources and potential milestone/royalty economics. Structurally, partnering with a major pharma reduces single‑asset risk, accelerates development options and increases commercial pathway probability over the medium term.
Multi-year Cash RunwayA $268.3M cash balance that management expects to fund operations through end‑2028 materially reduces near‑term financing risk. This allows the company to advance multiple clinical programs to key inflection points without immediate capital raises, supporting strategic optionality.
Platform And Clinical MomentumC4’s TORPEDO platform and advancing cemsidomide programs create multiple shots on goal across indications. Ongoing Phase 1/2 readouts and scientific presentations strengthen IP and partnering appeal, underpinning durable competitive positioning in targeted protein degradation.
Bears Say
Sustained Negative Cash FlowPersistent ~-$95M annual operating cash burn means the business consumes significant liquidity each year. Even with current runway, continued negative cash flow elevates refinancing and dilution risk if clinical progress or milestone payments slip, pressuring long‑term viability.
Deep Unprofitability Vs Modest RevenuesRevenue remains small while operating costs drive a deeply negative net margin (~-362%). High gross margins don't offset heavy R&D and SG&A spend; absent product revenues, profitability is unlikely near term, keeping returns dependent on successful commercialization or partner payouts.
Revenue Dependence And Capital Structure RiskBusiness model relies on collaborations, milestones and royalties rather than product sales, creating revenue timing uncertainty. Approval to include pre‑funded warrants in share count highlights potential equity dilution mechanics, increasing capital structure and funding risks over time.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics, Inc.’s price range in the past 12 months?
C4 Therapeutics, Inc. lowest stock price was $1.69 and its highest was $5.17 in the past 12 months.
What is C4 Therapeutics, Inc.’s market cap?
C4 Therapeutics, Inc.’s market cap is $407.99M.
When is C4 Therapeutics, Inc.’s upcoming earnings report date?
C4 Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were C4 Therapeutics, Inc.’s earnings last quarter?
C4 Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.051.
Is C4 Therapeutics, Inc. overvalued?
According to Wall Street analysts C4 Therapeutics, Inc.’s price is currently Undervalued.
Does C4 Therapeutics, Inc. pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
What is C4 Therapeutics, Inc.’s EPS estimate?
C4 Therapeutics, Inc.’s EPS estimate is -0.21.
How many shares outstanding does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has 110,567,220 shares outstanding.
What happened to C4 Therapeutics, Inc.’s price movement after its last earnings report?
C4 Therapeutics, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of C4 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (253.88% Upside)
$10.33 (253.88% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 306.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Company Description
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$10.33
▲(253.88% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.97% Insiders
8.63% Mutual Funds
4.11% Other Institutional Investors
73.52% Public Companies and
Individual Investors